Other

The United States of America, as Represented by the Secretary, Department of Health and Human Services

University System of Maryland

Thomas Jefferson University

Protiva Biotherapeutics, Inc.

The United States Army Medical Research and Materiel Command

Lisa E Hensley

Ian MacLachlan

Vandana Sood

Thomas W Geisbert

Marjorie Ann Robbins

Adam Judge

Matthias Johannes Schnell

Amy C H Lee

Christoph Wirblich

Reed F Johnson

Christopher M Coleman

Matthew B Frieman

Peter B Jarhling

Susan De Jong

Elliott Kagan

Matthew S Frieman

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

Multivalent vaccines for rabies virus and coronaviruses

The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a DNA metabolism inhibitor or an anti-parasitic agent. Also provided are methods for treating a coronavirus infection in which an anti-viral drug also is administered during any of the described methods.

Methods of treating coronavirus infection

The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.

Compositions and methods for silencing ebola virus gene expression

Compositions and methods for silencing Ebola virus gene expression

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target Lassa virus (LASV) or tissue factor (TF) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating hemorraghic fever).

Compositions and methods for silencing genes involved in hemorrhagic fever

The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.

siRNA silencing of filovirus gene expression

Growing community of inventors

Frederick, MD, United States of America

Lisa E Hensley